p21-Activated kinase inhibitors: a patent review

Author： Crawford James J   Hoeflich Klaus P   Rudolph Joachim  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.22, Iss.3, 2012-03, pp. : 293-310

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

p38α mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011)

By Fischer Stefan   Koeberle Solveigh C   Laufer Stefan A  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 12, 2011-12 ,pp. : 1843-1866

Informa Healthcare

Access to resources Recommend Favorite

Protein kinase CK2 inhibitors: a patent review

By Cozza Giorgio   Pinna Lorenzo A   Moro Stefano  

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 9, 2012-09 ,pp. : 1081-1097

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors of anaplastic lymphoma kinase: a patent review

By Milkiewicz Karen L   Ott Gregory R  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 12, 2010-12 ,pp. : 1653-1681

Informa Healthcare

Access to resources Recommend Favorite

Phosphoinositide 3-kinase α inhibitors: a patent review

By Denny William A  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 7, 2013-07 ,pp. : 789-799

Informa Healthcare

Access to resources Recommend Favorite

Checkpoint kinase inhibitors: a patent review (2009 –– 2010)

By Lainchbury Michael   Collins Ian  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 8, 2011-08 ,pp. : 1191-1210

Informa Healthcare

Access to resources Recommend Favorite